Ezz Life Science Holdings Ltd. · ASX:EZZ
Ezz Life Science — H1 2025 Earnings Presentation
16 slides from Ezz Life Science's earnings presentation, Feb 26, 2025
Slide 1: 1H FY25 Results Webinar
1H FY25 Results Webinar 26 February 2025 Glenn Cross, Non-Executive Chair Anthony Guarna, Chief Financial Officer
Slide 2: Disclaimer
DISCLAIMER This document has been prepared by EZZ Life Science Holdings Limited ACN 608 363 604 (Company). By accepting a copy of this document you warrant and undertake to the Company that you agree to be bound by the terms and conditions set out below. This document is not a prospectus, product di
Slide 3: The EZZ Mission
The EZZ Mission To become a leading life science company improving quality of life and human health by accelerating innovation to market. ASX: EZZ 3 Investor Presentation 1H FY2025
Slide 4: 1H FY25 Highlights
1H FY25 Highlights Strong Financial New Distribution Channels New Product Performance and Geographical Markets Development Revenue from operating activities increased Achieved 84% YoY revenue growth during the Successfully launched eight new products by 40% on PCP to $30.3m 2024 11.11 Global Shoppin
Slide 5: EZZ Brand Highlights
EZZ Brand Highlights EZZ-branded products continue to show strong growth in 1H FY25 EZZ-Branded Product Revenue B2C and Omnichannel Digital Marketing Revenue $28.3M Up 48% on PCP and accounting for 94% $25.7M of total revenue Up 37% on PCP Revenue from New Products 8 $1.2M New EZZ-Branded Product La
Slide 6: Diverse Product Range
Diverse Product Range We formulate, produce, market and distribute health We are an exclusive distributor of skin care supplements under the brand of EZZ. Our deep products under the EÁORON brand in Australia understanding of our target consumers allows us to and New Zealand to pharmacies, develop p
Slide 7: Extensive and Growing Distribution Channels
Extensive and Growing Distribution Channels In 1H FY25 EZZ added 14 new independent pharmacy stores to our expanding omnichannel distribution network Chemists Specialist and Grocery Retailers E-commerce Platforms 600+ 200+ 750+ ASX: EZZ 7 Investor Presentation 1H FY2025
Slide 8: Financials
Financials ASX: EZZ 8 Investor Presentation 1H FY2025
Slide 9: 1H FY25 Highlights
1H FY25 Highlights Cash on Hand Revenue from Operating Activities EBITDA (Excluding other income) $4.8M $19.9M $30.3M No external debt Up 40% on PCP Up 185% on PCP at 31 December 2024 Sales during the 2024 11.11 Global NPAT Gross Margin Increased to Shopping Festival $3.2M $5.9M 77% Up 180% on PCP f
Slide 10: 1H FY25 Revenue
1H FY25 Revenue Record revenue growth due to successful market-driven R&D, dynamic channel prioritisation, and targeted B2C marketing Revenue Drivers Revenue by Segment 1H FY24 1H FY25 $1.6M $30.3M $7.6M $28.3M -$0.5M -$0.1M $21.7M $19.1M $2.6M $2.0M Revenue, EZZ, Export Revenue, EAORON, Revenue, To
Slide 11: 1H FY25 Revenue Mix
1H FY25 Revenue Mix Increasingly diversified revenue streams across multiple distribution channels and geographic regions Revenue by Channel Revenue by Geography 1.3% 0.35% 0.03% Greater China 14.0% eCommerce 13.68% Pharmacy / specialist Australia retailer Supermarket / grocery New Zealand store and
Slide 12: 1H FY25 Profitability
1H FY25 Profitability Solid operating profit and strong growth momentum fuelled by successful investments in marketing EBITDA (Excluding Other Income) Operating Expense Breakdown $4.8M 7.6% 9.7% Others 4.1% Employee 4.0% 1.3% benefits 1.4% $1.8M $1.7M Depreciation and 87.0% amortisation 84.9% Advert
Slide 13: US Market Entry Strategy Update
US Market Entry Strategy Update Dedicated New Product Team Focus Launching four products high growth Appointed project team of four staff with identified areas across probiotics and backgrounds in marketing and gut health, women’s health and exercise biomedical science health Next Steps Update expec
Slide 14: Looking Forward
Looking Forward ▪ US Market Entry: Enhanced strategy and market entry expected in 2H FY25 ▪ New Products: Continue expanding product range with at least five new products in 2H FY25. ▪ China Growth: Continuing to capitalise on EZZ’s key market with ongoing investments in enhanced marketing and influ
Slide 15: Q&A
Q&A ASX: EZZ 15 Investor Presentation 1H FY2025
Slide 16: EZZ Life Science Holdings Limited
EZZ Life Science Holdings Limited EZZLifescience ASX: EZZ linkedin.com/company/e zz-life-science-holdings EZZAustralia Contact EZZ Life Science Holdings Limited ABN 83 608 363 604 EZZ_Australia 1/55-59 Parramatta Road Lidcombe NSW. 2141 T: 02 9160 2305 E: ir@ezzlife.com.au www.ezzlife.com.au
EZZ Life Science Holdings — H1 2025 Earnings Presentation on 6ix